Search results

Articles (5)

Journals (0)

1-5 of 5 results for SAR341402

Sort by:

Relevance

Select all

Sort by:

Relevance

Free accessResearch articleFirst published July, 2025

Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial

Viral N. Shah, Amer Al-Karadsheh, Cathy Barnes [...]

Journal of Diabetes Science and Technology

Open accessResearch articleFirst published April, 2020

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Christoph Kapitza, Leszek Nosek, Wolfgang Schmider [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published September, 2020

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized,Open-Label Clinical Trial

James Thrasher, Sarit Polsky, Lionel Hovsepian [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published July, 2020

Safety,Immunogenicity,and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published February, 2020

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Search results

Articles (5)

Journals (0)

1-5 of 5 results for SAR341402

Sort by:

Relevance

Select all

Sort by:

Relevance

Free accessResearch articleFirst published July, 2025

Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial

Viral N. Shah, Amer Al-Karadsheh, Cathy Barnes [...]

Journal of Diabetes Science and Technology

Open accessResearch articleFirst published April, 2020

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Christoph Kapitza, Leszek Nosek, Wolfgang Schmider [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published September, 2020

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized,Open-Label Clinical Trial

James Thrasher, Sarit Polsky, Lionel Hovsepian [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published July, 2020

Safety,Immunogenicity,and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published February, 2020

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics